Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.
about
Interventions for cough in cancerEfficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancerEfficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan.Leuprolide acetate 1-, 3- and 6-monthly depot formulations in androgen deprivation therapy for prostate cancer in nine European countries: evidence review and economic evaluation.Intramuscular depot formulations of leuprolide acetate suppress testosterone levels below a 20 ng/dL threshold: a retrospective analysis of two Phase III studies.Six-month leuprorelin acetate depot formulations in advanced prostate cancer: a clinical evaluation.Bioportides: bioactive cell-penetrating peptides that modulate cellular dynamics.Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer.Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects.A semi-mechanistic integrated pharmacokinetic/pharmacodynamic model of the testosterone effects of the gonadotropin-releasing hormone agonist leuprolide in prostate cancer patients.Recent discoveries and developments of androgen receptor based therapy for prostate cancerIn VitroCharacterization of Six Month Dosage Forms for a GnRH Antagonist
P2860
Q24187918-AE492C16-1B08-4129-BFE9-DA7E9CDC620EQ35797403-B0F5100C-DE46-42E7-BB0E-681E32F8FCC6Q36299818-42990727-88C7-478F-8CEE-D1CE8FEC7ADCQ36975113-CFFB6DE0-3712-49F7-AF37-1A1EFA77FFA9Q37214500-8F8B736F-100B-4718-A320-84379F094E37Q38103540-187CF402-137E-474C-8E92-999711AF1620Q38120721-C6BA47D4-B57F-46DB-B283-39B54E5C6CDAQ38570555-15C4753E-194F-4ABB-9BFE-6F40D8117368Q39003600-BAB1C85A-6EEB-495D-9BAB-908FDA2F5245Q49787745-ACDEBBCA-C553-427E-86CB-18B44BA57C84Q53571610-99B60341-9F19-404B-89A5-1DEBA594624BQ56621622-6BCDFA45-75DD-446E-BB5C-7A25EC321551Q59051344-30FBB990-EEED-41D9-AD88-C3CA74A89088
P2860
Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Efficacy and safety of leuprol ...... patients with prostate cancer.
@ast
Efficacy and safety of leuprol ...... patients with prostate cancer.
@en
type
label
Efficacy and safety of leuprol ...... patients with prostate cancer.
@ast
Efficacy and safety of leuprol ...... patients with prostate cancer.
@en
prefLabel
Efficacy and safety of leuprol ...... patients with prostate cancer.
@ast
Efficacy and safety of leuprol ...... patients with prostate cancer.
@en
P2093
P2860
P356
P1476
Efficacy and safety of leuprol ...... patients with prostate cancer.
@en
P2093
C Mattia-Goldberg
J Donnelly
K Chwalisz
P2860
P2888
P356
10.1038/PCAN.2011.50
P577
2011-10-25T00:00:00Z
P5875
P6179
1005125611